Kivu Bioscience News and Activities

Acquisition, funding and merger involving Kivu Bioscience.

• Kivu Bioscience has just announced a $92 Million fundraising (posted on November 6 2024).

View the org chart displaying its 20 main executives

Most searched biographies at Kivu Bioscience

• Mohit Trikha, Chief Executive Officer
• Max Klement, Director
• Daniel O'Connell, Chairman of the Board

Popular executive movements at Kivu Bioscience

• Mohit Trikha, who was President, Chief Operating Officer and Director, is promoted to Chief Executive Officer  (posted on April 14 2026).
• Brunilda Shtylla has joined the company as Chief Business Officer  (posted on March 4 2026).
• Julie Hambleton has joined the company as Director  (posted on January 27 2026).

Click here to view some more movements at Kivu Bioscience

Create your alert
to follow the executive moves at Kivu Bioscience.

Kivu Bioscience has 2,417 competitors including Lonza (Switzerland), Eurofins (Luxembourg) and Vertex Pharmaceuticals (United States (USA)).

Popular M&A news in Biotechnology

• Zymeworks has announced the acquisition of Theravance Biopharma  (posted on June 29 2026).
• Tissium has just announced a $68 Million fundraising (posted on June 29 2026).
• Oblenio Bio has just announced a $62 Million fundraising (posted on June 26 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Carl Gordon - Director at Odyssey Therapeutics
• Jan Van de Winkel - President and Chief Executive Officer at Genmab

Learn more about the Biotechnology industry

Press releases by Kivu Bioscience

• Kivu Bioscience to Present Preclinical Data on Next-Generation ADC Programs at AACR Annual Meeting 2026 - Kivu Bioscience
• Kivu Bioscience Appoints Mohit Trikha, Ph.D., as Chief Executive Officer - Kivu Bioscience
• Kivu Bioscience Appoints Brunilda Shtylla as Chief Business Officer - Kivu Bioscience
• Kivu Bioscience Presents KIVU-305 Preclinical Data at World ADC London 2026 and Advances into Phase 1 Clinical Trial - Kivu Bioscience
• Kivu Bioscience Appoints Julie Hambleton, M.D., to its Board of Directors - Kivu Bioscience
• Kivu Bioscience Announces First Patient Dosed in Phase 1 Trial of KIVU-107 Next-Generation PTK7-Targeting ADC for Advanced Solid Tumors - Kivu Bioscience
• Kivu Bioscience Appoints Sophia Randolph, M.D., Chief Medical Officer - Kivu Bioscience
• Kivu Bioscience Presents Preclinical Data for KIVU-107 Demonstrating Potent and Durable Anti-Tumor Activity and a Wide Therapeutic Index at World ADC San Diego 2025 - Kivu Bioscience
• Kivu Bioscience Selects Sterling Pharma Solutions for cGMP Manufacturing of Lead Oncology Antibody-Drug Conjugate KIVU-107 - Kivu Bioscience
• With $92M, Kivu sets out to make ‘kinder, gentler’ ADCs - Kivu Bioscience
• View more press releases Close

Social media about Kivu Bioscience

• Kivu Bioscience on Wikipedia, Google News & Yahoo Finance
• Kivu Bioscience on LinkedIn, X (Twitter) & YouTube